Fresenius Kabi announced that both the FDA and the EMA have accepted for review its applications for PB016, a biosimilar candidate to the biologic medicine Entyvio (vedolizumab). Acceptance for review is a significant regulatory milestone, meaning both agencies will now assess the medicine's safety, quality, and effectiveness before making approval decisions.
Vedolizumab is widely prescribed for treating moderately to severely active Crohn's disease and ulcerative colitis, two chronic inflammatory bowel diseases that affect millions of people globally. Biosimilars are developed to provide the same clinical benefits as the original biologic medicine while increasing competition, which can help reduce treatment costs and improve patient access.
According to Fresenius Kabi, the proposed biosimilar is intended to strengthen its portfolio of autoimmune disease treatments and support healthcare systems by offering an additional high-quality therapeutic option. Experts note that wider availability of biosimilars can expand access to life-changing medicines, particularly in countries where the high cost of biologic therapies limits patient treatment.
The FDA and EMA will now conduct detailed scientific reviews before reaching their final decisions. If approved, PB016 could become an important new treatment option for patients with inflammatory bowel disease while contributing to broader access to advanced biologic therapies around the world.
